Jefferies (NYSE:JEF) analyst Brandon Couillard maintained a Hold rating on Perkinelmer on Wednesday, setting a price target of $120, which is approximately 1.96% above the present share price of $117.69.
Couillard expects Perkinelmer to post earnings per share (EPS) of $1.23 for the third quarter of 2020.
The current consensus among 10 TipRanks analysts is for a Moderate Buy rating of shares in PerkinElmer (NYSE:PKI), with an average price target of $118.
The analysts price targets range from a high of $125 to a low of $105.
In its latest earnings report, released on 06/30/2020, the company reported a quarterly revenue of $811.72 million and a net profit of $176.8 million. The company's market cap is $13.06 billion.
According to TipRanks.com, Jefferies analyst Brandon Couillard is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 27.7% and a 75.52% success rate.
PerkinElmer, Inc. engages in the provision of products, services, and solutions for diagnostics, food, environmental, life sciences, and applied markets. It operates through the following segments: Discovery (NASDAQ:DISCA) & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment comprises of technologies that help life sciences researchers better understand diseases and develop treatments. The Diagnostics segment offers instruments, reagents, assay platforms, and software to hospitals, medical labs, clinicians, and medical research professionals to help improve the health of families. The company was founded by Richard Scott Perkin and Charles W. Elmer on April 19, 1937 and is headquartered in Waltham, MA.